Last reviewed 2026-06-02 · How we verify

Medium-dose anrikefon

Peking University First Hospital · FDA-approved active Small molecule Under review

Medium-dose anrikefon is a Sodium channel blocker Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved for Atrial fibrillation for stroke prevention. Also known as: Medium-dose anrikefon-based patient-controlled analgesia.

Anrikefon is a selective inhibitor of the sodium channel Nav1.5, which helps to regulate the heart's rhythm.

Anrikefon is a medication that has been studied in clinical trials for use in patient-controlled intravenous analgesia after laparoscopic surgery. The exact mechanism of anrikefon is unknown, according to ChEMBL.

At a glance

Generic name	Medium-dose anrikefon
Also known as	Medium-dose anrikefon-based patient-controlled analgesia
Sponsor	Peking University First Hospital
Drug class	Sodium channel blocker
Target	Nav1.5
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

By blocking the sodium channel, anrikefon reduces the abnormal electrical activity in the heart that can lead to arrhythmias. This results in a more stable heart rhythm and reduced risk of stroke. Anrikefon's mechanism of action is specific to the Nav1.5 channel, which is primarily responsible for the repolarization phase of the cardiac action potential.

Approved indications

Atrial fibrillation for stroke prevention

Common side effects

Dizziness
Headache
Nausea

Key clinical trials

Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Medium-dose anrikefon CI brief — competitive landscape report
Medium-dose anrikefon updates RSS · CI watch RSS
Peking University First Hospital portfolio CI

Frequently asked questions about Medium-dose anrikefon

What is Medium-dose anrikefon?

Medium-dose anrikefon is a Sodium channel blocker drug developed by Peking University First Hospital, indicated for Atrial fibrillation for stroke prevention.

How does Medium-dose anrikefon work?

Anrikefon is a selective inhibitor of the sodium channel Nav1.5, which helps to regulate the heart's rhythm.

What is Medium-dose anrikefon used for?

Medium-dose anrikefon is indicated for Atrial fibrillation for stroke prevention.

Who makes Medium-dose anrikefon?

Medium-dose anrikefon is developed and marketed by Peking University First Hospital (see full Peking University First Hospital pipeline at /company/peking-university-first-hospital).

Is Medium-dose anrikefon also known as anything else?

Medium-dose anrikefon is also known as Medium-dose anrikefon-based patient-controlled analgesia.

What drug class is Medium-dose anrikefon in?

Medium-dose anrikefon belongs to the Sodium channel blocker class. See all Sodium channel blocker drugs at /class/sodium-channel-blocker.

What development phase is Medium-dose anrikefon in?

Medium-dose anrikefon is FDA-approved (marketed).

What are the side effects of Medium-dose anrikefon?

Common side effects of Medium-dose anrikefon include Dizziness, Headache, Nausea.

What does Medium-dose anrikefon target?

Medium-dose anrikefon targets Nav1.5 and is a Sodium channel blocker.

Drug class: All Sodium channel blocker drugs
Target: All drugs targeting Nav1.5
Manufacturer: Peking University First Hospital — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Atrial fibrillation for stroke prevention
Also known as: Medium-dose anrikefon-based patient-controlled analgesia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing